Alnylam Pharmaceuticals, Inc. (ALNY)
236.20
-0.36
(-0.15%)
USD |
NASDAQ |
Aug 28, 14:23
Alnylam Pharmaceuticals Cash from Operations (Quarterly) : 326.72M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 326.72M |
| March 31, 2026 | 70.50M |
| December 31, 2025 | 163.56M |
| September 30, 2025 | 325.11M |
| June 30, 2025 | 129.81M |
| March 31, 2025 | -120.31M |
| December 31, 2024 | -94.66M |
| September 30, 2024 | 43.71M |
| June 30, 2024 | 124.16M |
| March 31, 2024 | -81.52M |
| December 31, 2023 | -29.80M |
| September 30, 2023 | 359.41M |
| June 30, 2023 | -58.99M |
| March 31, 2023 | -166.48M |
| December 31, 2022 | -131.98M |
| September 30, 2022 | -115.28M |
| June 30, 2022 | -122.82M |
| March 31, 2022 | -171.19M |
| December 31, 2021 | -150.14M |
| September 30, 2021 | -134.04M |
| June 30, 2021 | -121.86M |
| March 31, 2021 | -235.66M |
| December 31, 2020 | -123.14M |
| September 30, 2020 | -110.33M |
| June 30, 2020 | -135.33M |
| Date | Value |
|---|---|
| March 31, 2020 | -246.16M |
| December 31, 2019 | -195.98M |
| September 30, 2019 | -182.63M |
| June 30, 2019 | 288.70M |
| March 31, 2019 | -188.51M |
| December 31, 2018 | -150.46M |
| September 30, 2018 | -153.81M |
| June 30, 2018 | -102.69M |
| March 31, 2018 | -155.66M |
| December 31, 2017 | -103.04M |
| September 30, 2017 | -98.36M |
| June 30, 2017 | -81.05M |
| March 31, 2017 | -100.33M |
| December 31, 2016 | -78.34M |
| September 30, 2016 | -75.54M |
| June 30, 2016 | -70.20M |
| March 31, 2016 | -83.62M |
| December 31, 2015 | -53.06M |
| September 30, 2015 | -54.36M |
| June 30, 2015 | -55.46M |
| March 31, 2015 | -26.26M |
| December 31, 2014 | -36.64M |
| September 30, 2014 | -40.71M |
| June 30, 2014 | -46.62M |
| March 31, 2014 | -41.68M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | 565.53M |
| Regeneron Pharmaceuticals, Inc. | 813.00M |
| Vertex Pharmaceuticals, Inc. | 1.125B |
| BridgeBio Pharma, Inc. | -71.10M |
| Pfizer Inc. | 835.00M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -363.46M |
| Cash from Financing (Quarterly) | 36.24M |
| Free Cash Flow | 793.94M |
| Free Cash Flow Per Share (Quarterly) | 2.112 |
| Free Cash Flow to Equity (Quarterly) | 274.78M |
| Free Cash Flow to Firm (Quarterly) | 367.95M |
| Free Cash Flow Yield | 2.44% |